ENZON PHARMACEUTICALS, INC. (ENZN)

Latest Insider Confidence Score

2025Q4

50.0
Bullish

Company insider confidence (by quarter)

2003Q4 2025Q4

Largest shareholders

Insider Role (last 12 mo) Shares held Filed at
Icahn Carl C 10% Owner 36,056,636 Oct 14, 2020
Pearce Michael Cooper Other 7,851,454 Aug 26, 2020
Harper Brian James Other 7,851,454 Aug 26, 2020
Harper Asset Management Llc Other 7,851,454 Aug 26, 2020
Couchman Jonathan 10% Owner 5,350,930 Aug 17, 2021

Recent buy/sell transactions

Exec date Filing date Insider Role Signal Confidence Shares % of shares Under plan? Amount (USD)
Jan 10, 2025 WILLS STEPHEN T Director Neutral 52.5 - 0.00% ✗ -
Jun 14, 2023 Jun 16, 2023 READ RANDOLPH C Director Buy 91.3 +99,550 99.10% ✗ $13.9K
Jun 21, 2022 Firestone Jaffrey Adam Director Neutral 52.5 - 0.00% ✗ -
Aug 13, 2021 Aug 17, 2021 COUCHMAN JONATHAN 10% Owner Sell 26.3 -107,500 -1.37% ✗ $41.9K
Nov 16, 2020 Nov 18, 2020 READ RANDOLPH C Director Buy 91.3 +100,450 100.00% ✗ $15.5K
Nov 13, 2020 Nov 17, 2020 Bleznick Jordan Director Buy 91.3 +100,000 100.00% ✗ $15.4K
Oct 9, 2020 Oct 14, 2020 ICAHN CARL C 10% Owner Neutral 52.5 - 0.00% ✗ -
Aug 24, 2020 Aug 26, 2020 COUCHMAN JONATHAN 10% Owner Sell 36.3 -77,100 -0.81% ✗ $14.3K
Aug 18, 2020 Bleznick Jordan Director Neutral 52.5 - 0.00% ✗ -
Aug 14, 2020 READ RANDOLPH C Director Neutral 52.5 - 0.00% ✗ -
Aug 5, 2020 Aug 6, 2020 COUCHMAN JONATHAN 10% Owner Buy 90.0 +506,292 5.62% ✗ $101.3K
Aug 6, 2020 COUCHMAN JONATHAN 10% Owner Neutral 52.5 - 0.00% ✗ -
Mar 13, 2020 Mar 31, 2020 COUCHMAN JONATHAN 10% Owner Buy 90.0 +652,723 9.75% ✗ $91.3K
Mar 31, 2020 Myrexis, Inc. Other Neutral 52.5 - 0.00% ✗ -
Mar 13, 2020 Mar 27, 2020 COUCHMAN JONATHAN 10% Owner Buy 90.0 +652,723 9.75% ✗ $91.3K
Feb 11, 2019 Feb 14, 2019 COUCHMAN JONATHAN 10% Owner Buy 68.8 +51,000 0.77% ✗ $12.8K
Aug 15, 2018 Jan 9, 2019 COUCHMAN JONATHAN 10% Owner Buy 95.0 +950,623 16.71% ✗ $230.2K
Apr 13, 2018 Jan 9, 2019 COUCHMAN JONATHAN 10% Owner Buy 97.5 +998,402 27.91% ✗ $258.6K
Apr 13, 2018 COUCHMAN JONATHAN 10% Owner Neutral 52.5 - 0.00% ✗ -
Nov 28, 2016 Nov 29, 2016 ICAHN CARL C 10% Owner Buy 97.5 +694,023 11.75% ✗ $281.1K
Apr 5, 2016 Rackear Andrew D. CEO Neutral 52.5 - 0.00% ✗ -
Nov 28, 2012 Nov 28, 2014 ICAHN CARL C 10% Owner Neutral 27.5 -1,388,046 -10.52% ✗ -
Dec 13, 2013 FEINSTEIN RICHARD L VP-Finance and PFO Neutral 52.5 - 0.00% ✗ -
Oct 9, 2013 CHRISTODORO JONATHAN Director Neutral 52.5 - 0.00% ✗ -
Oct 7, 2013 McNealey Jennifer Isacoff Director Neutral 52.5 - 0.00% ✗ -
Oct 7, 2013 Kostas Odysseas D Director Neutral 52.5 - 0.00% ✗ -
Sep 17, 2013 Sep 19, 2013 LEBUHN ROBERT Director Sell 22.5 -55,926 -57.00% ✗ $96.1K
Jan 23, 2013 Jan 25, 2013 Rackear Andrew D. VP and General Counsel Neutral 85.0 +4,686 6.39% ✗ -
Jan 23, 2013 Jan 25, 2013 Buchbinder Aby VP, Clinical Development Neutral 82.5 +3,748 4.96% ✗ -
Jan 23, 2013 Jan 25, 2013 Conover Charles SVP, R&D Program Management Neutral 82.5 +2,343 3.23% ✗ -
Jan 2, 2013 Jan 4, 2013 Young Richard A Director Neutral 52.5 - 0.00% ✗ -
Jan 2, 2013 Jan 4, 2013 Deuel Thomas Director Neutral 52.5 - 0.00% ✗ -
Jan 2, 2013 Jan 4, 2013 SALISBURY ROBERT C Director Neutral 52.5 - 0.00% ✗ -
Jan 2, 2013 Jan 4, 2013 Mulligan Richard Director Neutral 52.5 - 0.00% ✗ -
Jan 2, 2013 Jan 4, 2013 LEBUHN ROBERT Director Neutral 52.5 - 0.00% ✗ -
Jan 2, 2013 Jan 4, 2013 DENNER ALEXANDER J Director Neutral 52.5 - 0.00% ✗ -
Nov 7, 2012 Nov 8, 2012 HEBARD GEORGE COO Neutral 90.0 +24,500 130.76% ✗ -
Aug 14, 2012 Aug 15, 2012 LEBUHN ROBERT Director Sell 26.3 -5,820 -5.60% ✗ $38.3K
Aug 10, 2012 Aug 13, 2012 LEBUHN ROBERT Director Sell 26.3 -1,933 -1.83% ✗ $12.7K
Jul 2, 2012 Jul 3, 2012 Young Richard A Director Neutral 90.0 +10,669 54.54% ✗ -
Jul 2, 2012 Jul 3, 2012 SALISBURY ROBERT C Director Neutral 90.0 +10,669 18.71% ✗ -
Jul 2, 2012 Jul 3, 2012 LEBUHN ROBERT Director Neutral 90.0 +10,669 11.21% ✗ -
Jul 2, 2012 Jul 3, 2012 Deuel Thomas Director Neutral 90.0 +10,669 49.48% ✗ -
Jul 2, 2012 Jul 3, 2012 Mulligan Richard Director Neutral 90.0 +18,670 61.43% ✗ -
Jul 2, 2012 Jul 3, 2012 DENNER ALEXANDER J Director Neutral 90.0 +21,338 54.32% ✗ -
Jun 20, 2012 Jun 21, 2012 HEBARD GEORGE COO Buy 91.3 +5,000 36.40% ✗ $34.4K
Jun 5, 2012 Jun 6, 2012 Rackear Andrew D. VP and General Counsel Sell 26.3 -1,614 -2.77% ✗ $11K
Jun 5, 2012 Jun 6, 2012 Conover Charles SVP, R&D Program Management Sell 22.5 -25,000 -30.41% ✗ $169.5K
Mar 28, 2012 Mar 29, 2012 Daly Timothy VP, Controller and PAO Neutral 90.0 +8,000 100.00% ✗ -
Mar 15, 2012 Mar 16, 2012 Young Richard A Director Sell 26.3 -2,000 -9.28% ✗ $13.8K
Feb 27, 2012 Feb 29, 2012 HEBARD GEORGE Director Neutral 90.0 +13,737 100.00% ✗ -
Feb 29, 2012 HEBARD GEORGE Director Neutral 52.5 - 0.00% ✗ -
Feb 28, 2012 ICAHN CARL C 10% Owner Neutral 52.5 - 0.00% ✗ -
Nov 17, 2011 Jan 19, 2012 Stancic Ana CFO Neutral 52.5 - 0.00% ✗ -
Jan 17, 2012 Jan 19, 2012 Buchbinder Aby VP, Clinical Development Neutral 85.0 +4,000 7.41% ✗ -
Jan 17, 2012 Jan 19, 2012 Conover Charles SVP, R&D Program Management Neutral 90.0 +10,000 13.63% ✗ -
Jan 17, 2012 Jan 19, 2012 Rackear Andrew D. VP and General Counsel Neutral 90.0 +10,000 20.69% ✗ -
Jan 17, 2012 Jan 19, 2012 Greenberger Lee M VP, Research Neutral 90.0 +3,500 10.72% ✗ -
Jan 17, 2012 Jan 19, 2012 Stancic Ana CFO Neutral 52.5 - 0.00% ✗ -
Jan 3, 2012 Jan 5, 2012 Deuel Thomas Director Neutral 52.5 - 0.00% ✗ -
Jan 3, 2012 Jan 5, 2012 Mulligan Richard Director Neutral 52.5 - 0.00% ✗ -
Jan 3, 2012 Jan 5, 2012 SALISBURY ROBERT C Director Neutral 52.5 - 0.00% ✗ -
Jan 3, 2012 Jan 5, 2012 Young Richard A Director Neutral 52.5 - 0.00% ✗ -
Jan 3, 2012 Jan 5, 2012 LEBUHN ROBERT Director Neutral 52.5 - 0.00% ✗ -
Jan 3, 2012 Jan 5, 2012 DENNER ALEXANDER J Director Neutral 52.5 - 0.00% ✗ -
Jan 5, 2012 Conover Charles SVP, R&D Program Management Neutral 52.5 - 0.00% ✗ -
Dec 19, 2011 Dec 20, 2011 Daly Timothy VP, Controller and PAO Neutral 52.5 - 0.00% ✗ -
Dec 20, 2011 Daly Timothy VP, Controller and PAO Neutral 52.5 - 0.00% ✗ -
Nov 17, 2011 Nov 21, 2011 Stancic Ana CFO Neutral 90.0 +45,000 180.00% ✗ -
Nov 10, 2011 Nov 10, 2011 Rackear Andrew D. VP and General Counsel Sell 26.3 -3,766 -7.23% ✗ $25.2K
Nov 8, 2011 Nov 10, 2011 Buchbinder Aby VP, Clinical Development Sell 26.3 -2,700 -4.76% ✗ $19.1K
Sep 15, 2011 Sep 19, 2011 Greenberger Lee M VP, Research Sell 27.5 -591 -1.78% ✗ $4.9K
Sep 15, 2011 Sep 19, 2011 del Campo Ralph COO Sell 45.0 -886 -0.43% ✗ $7.4K
Sep 15, 2011 Sep 19, 2011 Rackear Andrew D. VP and General Counsel Sell 26.3 -2,067 -3.82% ✗ $17.2K
Sep 15, 2011 Sep 19, 2011 Buchbinder Aby VP, Clinical Development Sell 26.3 -2,952 -4.95% ✗ $24.6K
Aug 12, 2011 Aug 16, 2011 Buchbinder Aby VP, Clinical Development Neutral 90.0 +8,000 15.48% ✗ -
Aug 12, 2011 Aug 16, 2011 Rackear Andrew D. VP and General Counsel Neutral 90.0 +10,000 22.64% ✗ -
Aug 12, 2011 Aug 16, 2011 del Campo Ralph COO Neutral 90.0 +35,000 20.63% ✗ -
Aug 1, 2011 Greenberger Lee M VP, Research Neutral 52.5 - 0.00% ✗ -
Aug 1, 2011 Rackear Andrew D. VP and General Counsel Neutral 52.5 - 0.00% ✗ -
Aug 1, 2011 Buchbinder Aby VP, Clinical Development Neutral 52.5 - 0.00% ✗ -
Jul 1, 2011 Jul 6, 2011 DENNER ALEXANDER J Director Neutral 90.0 +14,764 60.22% ✗ -
Jul 1, 2011 Jul 6, 2011 Deuel Thomas Director Neutral 90.0 +7,382 52.06% ✗ -
Jul 1, 2011 Jul 6, 2011 Mulligan Richard Director Neutral 90.0 +12,919 73.93% ✗ -
Jul 1, 2011 Jul 6, 2011 Young Richard A Director Neutral 90.0 +7,382 52.06% ✗ -
Jul 1, 2011 Jul 6, 2011 LEBUHN ROBERT Director Neutral 85.0 +7,382 8.41% ✗ -
Jul 1, 2011 Jul 6, 2011 SALISBURY ROBERT C Director Neutral 90.0 +7,382 14.87% ✗ -
Jul 1, 2011 Jul 6, 2011 Davit Paul Stephen Exec. Vice Pres. HR Sell 26.3 -1,969 -1.77% ✗ $20K
Jun 8, 2011 Jun 9, 2011 Stancic Ana CFO Neutral 90.0 +25,000 100.00% ✗ -
Jun 9, 2011 Stancic Ana CFO Neutral 52.5 - 0.00% ✗ -
Jun 1, 2011 Jun 2, 2011 LEBUHN ROBERT Director Sell 22.5 -8,702 -100.00% ✗ $92K
Apr 3, 2011 Apr 5, 2011 HORAK IVAN D EVP, R&D, CSO Sell 22.5 -9,380 -6.34% ✗ $103.4K
Apr 3, 2011 Apr 5, 2011 del Campo Ralph COO Sell 22.5 -5,951 -3.39% ✗ $65.6K
Apr 3, 2011 Apr 5, 2011 Davit Paul Stephen Exec. Vice Pres. HR Sell 26.3 -3,767 -3.27% ✗ $41.5K
Mar 30, 2011 Apr 1, 2011 HORAK IVAN D EVP, R&D, CSO Sell 77.5 +1,614 1.35% ✗ $9.5K
Mar 30, 2011 Apr 1, 2011 del Campo Ralph COO Sell 77.5 +1,614 1.03% ✗ $9.5K
Mar 30, 2011 Apr 1, 2011 Davit Paul Stephen Exec. Vice Pres. HR Sell 67.5 +939 0.93% ✗ $4.2K
Feb 28, 2011 Mar 1, 2011 Ogden Mark L Acting VP of Fin & Prin FO Buy 91.3 +2,000 100.00% ✗ $21.3K
Feb 28, 2011 ICAHN CARL C 10% Owner Neutral 52.5 - 0.00% ✗ -
Feb 22, 2011 Feb 24, 2011 LEBUHN ROBERT Director Sell 22.5 -10,000 -9.39% ✗ $108.8K